A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis

References

• World Health OrganizationCancer Pain Relief2nd edGenevaWorld Health Organization1996 Available from http://apps.who.int/iris/bitstream/10665/37896/1/9241544821.pdfAccessed July 26, 2017
   Google Scholar
• CaraceniAHanksGKaasaSEuropean Palliative Care Research Collaborative (EPCRC)European Association for Palliative Care (EAPC)Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCLancet Oncol2012132e58e6822300860
   PubMed Web of Science ®Google Scholar
• WiffenPJEvidence-based pain management and palliative care in issue one for 2005 of The Cochrane LibraryJ Pain Palliat Care Pharmacother2005193656816219616
   PubMedGoogle Scholar
• CorliOMontanariMDeandreaSGrecoMTVillaniWApoloneGAn exploratory analysis on the effectiveness of four strong opioids in patients with cancer painPain Med201213789790722680789
   PubMed Web of Science ®Google Scholar
• ManciniIBrueraEConstipation in advanced cancer patientsSupport Care Cancer1998643563649695203
   PubMed Web of Science ®Google Scholar
• RipamontiCISantiniDMaranzanoEBertiMRoilaFESMO Guidelines Working GroupManagement of cancer pain: ESMO Clinical Practice GuidelinesAnn Oncol201223Suppl 7vii139vii15422997447
   PubMed Web of Science ®Google Scholar
• Mundipharma Pharmaceuticals LimitedTargin 5/2.5 mg, 10 mg/5 mg, 20 mg/10 mg and 40/20 mg prolonged release tablets: summary of Product Characteristics2013 Available from: http://www.medicines.ie/medicine/14383/SPC/Targin+10mg+5mg+and+20mg+10mg+prolonged+release+tablets/Accessed February 8, 2017
   Google Scholar
• BurnessCBKeatingGMOxycodone-naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipationDrugs201474335337524452879
   PubMed Web of Science ®Google Scholar
• KoopmansGSimpsonKDe AndresJLuxEAWagemansMVan MegenYFixed ratio (2:1) prolonged-release oxycodone-naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxativesCurr Med Res Opin201430112389239625265132
   PubMed Web of Science ®Google Scholar
• PoelaertJKoopmans-KleinGDiohATreatment with prolonged-release oxycodone-naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipationClin Ther201537478479225757607
   PubMed Web of Science ®Google Scholar
• CuomoARussoGEspositoGForteCAConnolaMMarcassaCEfficacy and gastrointestinal tolerability of oral oxycodone-naloxone combination for chronic pain in outpatients with cancer: an observational studyAm J Hosp Palliat Care201431886787624249829
   PubMed Web of Science ®Google Scholar
• LazzariMGrecoMTMarcassaCFinocchiSCaldaruloCCorliOEfficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naive cancer patients: a propensity analysisDrug Des Devel Ther2015958635872
   PubMed Web of Science ®Google Scholar
• ApoloneGDeandreaSMontanariMCorliOGrecoMTCavutoSEvaluation of the comparative analgesic effectiveness of transdermal and oral opioids in cancer patients: a propensity score analysisEur J Pain201216222923822323375
   PubMed Web of Science ®Google Scholar
• D’AgostinoRBJrPropensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStat Med19981719226522819802183
   PubMed Web of Science ®Google Scholar
• CorliOFlorianiIRobertoACERP Study OF Pain Group (List of collaborators)CERP Study of Pain GroupAre strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioidsAnn Oncol20162761107111526940689
   PubMed Web of Science ®Google Scholar
• BouhassiraDAttalNAlchaarHComparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)Pain20051141–2293615733628
   PubMed Web of Science ®Google Scholar
• DaviesANDickmanAReidCStevensAMZeppetellaGScience Committee of the Association for Palliative Medicine of Great Britain and IrelandThe management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and IrelandEur J Pain200913433133818707904
   PubMed Web of Science ®Google Scholar
• TamburiniMRossoSGambaAMencagliaEDe ConnoFVentafriddaVA therapy impact questionnaire for quality-of-life assessment in advanced cancer researchAnn Oncol1992375655701498079
   PubMed Web of Science ®Google Scholar
• CorliOMontanariMGrecoMTHow to evaluate the effect of pain treatments in cancer patients: results from a longitudinal outcomes and endpoint Italian cohort studyEur J Pain201317685886623213042
   PubMed Web of Science ®Google Scholar
• KaasaSApoloneGKlepstadPEuropean Palliative Care Research Collaborative (EPCRC)European Association for Palliative Care Research Network (EAPCRN)Expert conference on cancer pain assessment and classification–the need for international consensus: working proposals on international standardsBMJ Support Palliat Care201113281287
   PubMedGoogle Scholar
• MercadanteSFulfaroFCasuccioABarresiLInvestigation of an opioid response categorization in advanced cancer patientsJ Pain Symptom Manage199918534735210584458
   PubMed Web of Science ®Google Scholar
• CavutoSBraviFGrassiMCApoloneGPropensity score for the analysis of observational data: an introduction and an illustrative exampleDrug Dev Res2006673208216
   Web of Science ®Google Scholar
• RosenbaumPRRubin DB. The central role of the propensity score in observational studies for causal effectsBiometrika19837014155
   Web of Science ®Google Scholar
• DworkinRHTurkDCWyrwichKWInterpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendationsJ Pain20089210512118055266
   PubMed Web of Science ®Google Scholar
• FarrarJTPortenoyRKBerlinJAKinmanJLStromBLDefining the clinically important difference in pain outcome measuresPain200088328729411068116
   PubMed Web of Science ®Google Scholar
• FarrarJTPritchettYLRobinsonMPrakashAChappellAThe clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disordersJ Pain201011210911819665938
   PubMed Web of Science ®Google Scholar
• FarrarJTYoungJPJrLaMoreauxLWerthJLPooleRMClinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePain200194214915811690728
   PubMed Web of Science ®Google Scholar
• SchutterUGrunertSMeyerCSchmidtTNolteTInnovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practiceCurr Med Res Opin20102661377138720380506
   PubMed Web of Science ®Google Scholar
• BenyaminRTrescotAMDattaSOpioid complications and side effectsPain Physician200811Suppl 2S105S12018443635
   PubMed Web of Science ®Google Scholar
• ClarkAJAhmedzaiSHAllanLGEfficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer painCurr Med Res Opin20042091419142815383190
   PubMed Web of Science ®Google Scholar
• TassinariDSartoriSTamburiniETransdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trialsJ Palliat Care200925317218019824278
   PubMed Web of Science ®Google Scholar
• WiffenPJDerrySMooreRAImpact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer painCochrane Database Syst Rev20145CD01105624874470
   PubMed Web of Science ®Google Scholar
• BrookhartMASchneeweissSRothmanKJGlynnRJAvornJSturmerTVariable selection for propensity score modelsAm J Epidemiol2006163121149115616624967
   PubMed Web of Science ®Google Scholar
• AhmedzaiSHNauckFBar-SelaGBosseBLeyendeckerPHoppMA randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer painPalliat Med2012261506021937568
   PubMed Web of Science ®Google Scholar